GLP-1 Receptor Agonists Show Superior Albuminuria Reduction Over SGLT-2 Inhibitors in Type 2 Diabetes Nephropathy
Background
Managing type 2 diabetes mellitus (T2DM) extends beyond glycemic control to mitigating severe complications like diabetic nephropathy (DN), a leading cause of end-stage renal disease. Current standard-of-care often falls short in comprehensively addressing both glycemic and renal protection, necessitating therapies with broader benefits. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have independently demonstrated cardiovascular and renal protective effects. However, direct comparative evidence on their efficacy in specific renal outcomes, particularly albuminuria, in patients with nascent DN remains limited, presenting a critical gap in guiding treatment strategies.
Study Design
This retrospective cohort study included 115 adults (≥18 years) with T2DM and a baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2, treated with either GLP-1RAs or SGLT-2i for over 1 year at King Fahad University Hospital. Patients on renal replacement therapy, nephrotoxic drugs, or with incomplete records were excluded. The cohort comprised 67.8% on SGLT-2i and 32.2% on GLP-1RAs. Primary endpoints included changes in eGFR, urine albumin/creatinine ratio (UACR), and hemoglobin A1c (HbA1c). Data were analyzed using Jeffrey's Amazing Statistics Program, with statistical significance set at p < 0.05.
Results
Both GLP-1RA and SGLT-2i groups showed minimal improvements in glycemic control. Hemoglobin A1c (HbA1c) decreased from 7.86% to 7.66% in the SGLT-2i group and from 8% to 7.76% in the GLP-1RA group. Estimated GFR (eGFR) changes were also modest, with GLP-1RAs showing a minimal improvement of 0.5-1.2 mL/min/1.73m2, while SGLT-2i exhibited a wider range of change from -1.2 to +10.1 mL/min/1.73m2. However, a significant divergence was observed in albuminuria:
The urine albumin/creatinine ratio (UACR) dropped by 13.35 mg/g with GLP-1RAs, whereas it unexpectedly increased by 49.86 mg/g in the SGLT-2i treated group. This suggests a distinct and more favorable impact of GLP-1RAs on reducing albuminuria, a key marker of renal damage, despite comparable overall glycemic and eGFR benefits between the two drug classes in this cohort.
Key Findings
- GLP-1RAs reduced urine albumin/creatinine ratio by 13.35 mg/g.
- SGLT-2i increased urine albumin/creatinine ratio by 49.86 mg/g.
- Both GLP-1RAs and SGLT-2i provided minimal HbA1c improvements (GLP-1RAs: 8% to 7.76%; SGLT-2i: 7.86% to 7.66%).
- eGFR changes were modest in both groups, with GLP-1RAs showing 0.5-1.2 mL/min/1.73m2 improvement.
Why It Matters
This study highlights a critical distinction in renal protection, suggesting that GLP-1RAs may offer superior benefits in reducing albuminuria compared to SGLT-2 inhibitors in patients with early diabetic nephropathy. For clinicians and patients, this finding could influence treatment selection, particularly when managing microalbuminuria or early signs of kidney damage in T2DM. While both drug classes are valuable, the specific advantage of GLP-1RAs in reducing albumin excretion could lead to more targeted therapeutic strategies. This suggests that combining these agents, or prioritizing GLP-1RAs in patients with significant albuminuria, might optimize renal outcomes. Further research is needed to translate these findings into definitive clinical protocols and understand the underlying mechanisms for this differential effect on albuminuria.
glp-1ra
sglt-2i
diabetic-nephropathy
type-2-diabetes
albuminuria
renal-protection